Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres











Base de données
Gamme d'année
2.
J Biol Regul Homeost Agents ; 34(4 Suppl. 2): 47-53. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY, 2020.
Article de Anglais | MEDLINE | ID: mdl-33000600

RÉSUMÉ

Kawasaki disease (KD) is an acute systemic vasculitis of unknown etiology. It has a self-limiting course and so far, represents the most common cause of coronary heart disease acquired in children aged between 6 months and 5 years. The inflammatory process can involve the coronary arteries with the formation of aneurysms and thrombotic occlusions with the risk of sudden death, especially in infants. Myocardial inflammation and abnormalities of cardiac contractility can occur acutely or many years after the disease onset. Therapy must be started within 10 days after the onset of symptoms to reduce the risk of heart complications. Immunoglobulin and aspirin treatment are effective in reducing heart complications. Recent studies have shown new therapeutic strategies (corticosteroids, immunosuppressive and biological drugs) in case of ineffectiveness of treatment with immunoglobulins.


Sujet(s)
Cardiopathies , Maladie de Kawasaki , Enfant d'âge préscolaire , Vaisseaux coronaires , Cardiopathies/étiologie , Humains , Nourrisson , Maladie de Kawasaki/complications , Maladie de Kawasaki/diagnostic , Maladie de Kawasaki/traitement médicamenteux
3.
J Biol Regul Homeost Agents ; 34(4 Suppl. 2): 59-62. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY, 2020.
Article de Anglais | MEDLINE | ID: mdl-33000602
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE